MNOV

Medicinova, Inc.

1.40

USD

-0.07

-4.76%

Oct 29, 15:59 UTC -4

Closed

Pre-Market

1.40

0.00

0.00%

Medicinova, Inc. (MNOV) Earnings

MNOV Earnings Reports

Positive Surprise Ratio

MNOV beat 31 of 41 last estimates.

76%

Next Report

Date of Next Report

Nov 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

$51.00K

-$0.06

Implied change from Q2 26 (Revenue/ EPS)

-88.86%

+20.00%

Implied change from Q3 25 (Revenue/ EPS)

-58.64%

Medicinova, Inc. earnings per share and revenue

On Aug 13, 2026, MNOV reported earnings of -0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.06 USD, resulting in a 22.60% surprise. Revenue reached 458.00 thousand, compared to an expected 51.00 thousand, with a 798.04% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.06 USD, with revenue projected to reach 51.00 thousand USD, implying an increase of 20.00% EPS, and decrease of -88.86% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

Phathom Pharmaceuticals, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.14

Actual

$0.04

Surprise

+128.27%

Gilead Sciences Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.24

Actual

$2.54

Surprise

+13.66%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

Ligand Pharmaceuticals Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.42

Actual

$2.67

Surprise

+9.91%

FAQ

What were Medicinova, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Medicinova, Inc. reported EPS of -$0.05, beating estimates by 22.6%, and revenue of $458.00K, 798.04% above expectations.

How did the market react to Medicinova, Inc.'s Q2 2026 earnings?

The stock price moved -- 0%, changed from $1.31 before the earnings release to $1.31 the day after.

When is Medicinova, Inc. expected to report next?

The next earning report is scheduled for Nov 11, 2026.

What are the forecasts for Medicinova, Inc.'s next earnings report?

Based on -- analysts, Medicinova, Inc. is expected to report EPS of -$0.06 and revenue of $51.00K for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.